Get the Stockscreener App
65.69
2.75%
-1.86
Vaxcyte Inc stock is traded at $65.69, with a volume of 916.91K.
It is down -2.75% in the last 24 hours and up +10.94% over the past month.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
See More
Previous Close:
$67.55
Open:
$67.72
24h Volume:
916.91K
Relative Volume:
0.17
Market Cap:
$10.34B
Revenue:
Net Income/Loss:
$-946.53M
P/E Ratio:
-9.4295
EPS:
-6.9664
Net Cash Flow:
$-814.94M
1W Performance:
+1.04%
1M Performance:
+10.94%
6M Performance:
+8.67%
1Y Performance:
+49.50%
1-Day Range:
$65.44
$68.33
1-Week Range:
$64.78
$72.89
52-Week Range:
$39.87
$90.75
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
65.69 | 10.34B | 0 | -946.53M | -814.94M | -6.9664 |
VRTX
Vertex Pharmaceuticals Inc
|
510.13 | 129.30B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.70 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.21 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.95 | 41.96B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Reiterated | Needham | Buy |
| Sep-12-25 | Initiated | Goldman | Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet - Zacks Investment Research
Vaxcyte EVP, COO Jim Wassil sells $1.56m in shares By Investing.com - Investing.com South Africa
Vaxcyte EVP, COO Jim Wassil sells $1.56m in shares - Investing.com
Vaxcyte Finalizes $575M Convertible Senior Notes and Equity Offering in October 2026 - Kalkine Media
Vaxcyte Closes Offerings of Common Stock, Warrants, and Senior Notes - marketscreener.com
Vaxcyte Announces Closing of $1.15 Billion Public Offerings - GlobeNewswire
Vaxcyte Inc Stock (PCVX) Moved Up by 9.47% on Oct 9: What Signal Does It Send? - TradingKey
Latham Advises on Vaxcyte Concurrent Public Offerings of Common Stock Pre Funded Warrants - Latham & Watkins LLP
Vaxcyte Announces Pricing for $500M Convertible Notes and 7.4M Share Offering - Kalkine Media
About $500 million is expected from stock and $500 million from bonds. Vaxcyte plans to fund vaccine work. - Stock Titan
Vaxcyte prices US$1B in stock, warrants and convertible notes - Mugglehead Investment Magazine
Vaxcyte stock reports OPUS-1 success after a 9.65 percent drop - AD HOC NEWS
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes - GlobeNewswire Inc.
Vaxcyte Announces Pricing of Concurrent Public Offerings of - GlobeNewswire
Biotech Stocks At 52-Week HighsPCVX +31% On Phase 3 Results, INFU, ILMN +7%, CRL+7%, HTFL +5% - RTTNews
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? - Zacks Investment Research
Two proposed $500 million offerings could fund Vaxcyte vaccine trials and U.S. launch preparations. - stocktitan.net
Vaxcyte stock falls on $1B dual offering launch - Yahoo Finance
Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge - The Motley Fool
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes - marketscreener.com
Vaxcyte, Inc.Common Stock (Nasdaq:PCVX) Stock Quote - FinancialContent
An officer proposes to sell $1.65M in Vaxcyte (PCVX) shares acquired by exercising stock options. - Stock Titan
An officer proposes selling Vaxcyte (PCVX) shares acquired by exercising stock options for cash. - stocktitan.net
Vaxcyte, Inc. (PCVX) Stock Price, News, Quote & History - ca.finance.yahoo.com
Vaxcyte EVP Jim Wassil Executes Stock Option and Sells Shares via Rule 10b5-1 Plan - Kalkine Media
A 2,250-share sale is proposed by Vaxcyte (PCVX) officer James Wassil. - Stock Titan
Total common shares outstanding of Vaxcyte, Inc. – HAN:5VA - TradingView
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
Trading the Move, Not the Narrative: (PCVX) Edition - Stock Traders Daily
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com - Investing.com South Africa
Vaxcyte CFO Andrew Guggenhime Forfeits 7,155 Shares, 7% of Holdings at $60.36 Each - Kalkine Media
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com - Investing.com Nigeria
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com - Investing.com Canada
Vaxcyte EVP Jim Wassil sells $163,862 in company stock - Investing.com
Vaxcyte (PCVX) officer plans stock sale after RSU vest - Stock Titan
Vaxcyte at Cantor conference: broad vaccine bet nears key test By Investing.com - Investing.com Canada
PCVX: VAX-31 phase III data expected by end of October, targeting broader pneumococcal protection - TradingView
Vaxcyte EVP Jim Wassil sells $163,862 in company stock - Investing.com
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com Nigeria
Why Are Vaxcyte (NASDAQ:PCVX) Shares Under Pressure After A Timeline Update? - Kalkine Media
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com Canada
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com UK
Vaxcyte Executive Sells Shares for Tax Obligations - Intellectia AI
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Globe and Mail
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know - The Globe and Mail
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Globe and Mail
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Motley Fool
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - Yahoo Finance
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know - The Globe and Mail
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vaxcyte Inc Stock (PCVX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cowan Elvia | Officer |
Oct 05 '26 |
Proposed Sale |
86.74 |
19,000 |
1,648,060 |
0 |
| Wassil Jim | Officer |
Oct 05 '26 |
Proposed Sale |
86.74 |
18,000 |
1,561,320 |
0 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO |
Oct 05 '26 |
Sale |
86.74 |
18,000 |
1,561,320 |
145,435 |
| Cowan Elvia | SVP, Finance & CAO |
Oct 05 '26 |
Option Exercise |
25.92 |
19,000 |
492,480 |
46,860 |
| Cowan Elvia | SVP, Finance & CAO |
Oct 05 '26 |
Sale |
86.74 |
19,000 |
1,648,060 |
27,860 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO |
Oct 01 '26 |
Sale |
56.67 |
2,250 |
127,513 |
145,435 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO |
Oct 01 '26 |
Option Exercise |
5.35 |
2,250 |
12,038 |
147,685 |
| Wassil Jim | Officer |
Oct 01 '26 |
Proposed Sale |
56.73 |
2,250 |
127,642 |
0 |
| Wassil Jim | Officer |
Sep 09 '26 |
Proposed Sale |
59.99 |
1,334 |
80,027 |
0 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO |
Sep 09 '26 |
Sale |
59.52 |
1,334 |
79,401 |
145,435 |
0.42%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):